Why experts advise against it for breast, skin and gynecologic cancers
Novel drugs included in therapy
Collaborating to treat this emerging complication of CPI
Data analyzed from three centers
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Test helpful for SLN-negative, stage I to IIA and thin tumors
Earlier detection of certain cancers a likely result
Toward detailed, personalized maps of identified and interpreted genomic variation
Refractory patients respond to combination therapy
First agent in a new class of noncytotoxic cancer drugs
Understanding resistance in PARP inhibitor therapy
Advertisement
Advertisement